RESEARCH
PUBLICATIONS
NEXTBIO COMMUNITY
-
Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?
Authors: Melinda T Coughlan, Vicki Thallas-Bonke, Josefa Pete, David M Long, Anna Gasser, David C K Tong, Maryann Arnstein, Suzanne R Thorpe, Mark E Cooper, Josephine M Forbes
Endocrinology 2007 Feb -
Alagebrium attenuates acute methylglyoxal-induced glucose intolerance in Sprague-Dawley rats.
Authors: Arti Dhar, Kaushik M Desai, Lingyun Wu
British journal of pharmacology 2010 Jan
Thought leaders and organizations working on research involving alagebrium.
- Synvista Therapeutics, Inc
- Baker Heart Research Institute
- Baker Medical Research Institute
- University of Saskatchewan
- Joslin Diabetes Center
- Johns Hopkins University School of Medicine
-
Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria
conditions: Diabetes Mellitus, Type 1 ; Diabetic Nephropathy
interventions: Alagebrium ; Placebo
-
Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I)
conditions: Diastolic Heart Failure
interventions: alagebrium ; placebo
Community
